Last 48 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 6.71 | — | 7.63 | 0.38 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 0.48 | 1.35 | 0.94 | 0.19 | 0.28 | 0.65 | 1.11 | 2.48 | 7.63 | 4.62 | 26.42 | 21.50 | 43.72 | 2964.18 | 333.02 | 5315.60 | — | — | 7222.96 | 10321.41 | 4842.18 |
| — | +108.5% | -15.2% | -92.2% | -96.3% | -85.9% | -95.8% | -88.5% | -82.5% | -99.8% | -92.1% | -99.6% | — | — | -95.4% | -48.5% | — | — | +395.9% | +428.3% | +58.4% | |
| P/B Ratio | 1.23 | 1.79 | 1.57 | 0.92 | 3.08 | 3.14 | 2.03 | 2.56 | 2.20 | 1.48 | 4.14 | 4.83 | 5.14 | 4.18 | 4.13 | 4.23 | 2.26 | 3.09 | 14.76 | 16.29 | 18.90 |
| — | -43.1% | -22.8% | -64.1% | +40.0% | +112.3% | -50.9% | -47.0% | -57.2% | -64.6% | +0.3% | +14.2% | +127.1% | +35.2% | -72.0% | -74.0% | -88.0% | -83.1% | -11.8% | -27.7% | -23.2% | |
| P/FCF | 15.03 | 13.42 | — | 0.66 | 8.31 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | 2.59 | — | 4.17 | 0.16 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | 3.81 | — | 4.59 | 0.16 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 63.0% | 42.9% | 100.0% | 100.0% | 100.0% | — | — | 100.0% | 100.0% | 100.0% |
| — | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | +58.7% | +133.2% | 0.0% | 0.0% | -37.0% | — | — | 0.0% | 0.0% | — | — | 0.0% | 0.0% | 0.0% | |
| Operating Margin | 7.6% | — | 13.2% | 53.2% | -10.8% | -36.8% | -71.5% | -75.7% | -293.4% | -254.0% | -1103.6% | -520.8% | -848.3% | -76843.3% | -9198.6% | -141536.4% | — | — | -29148.2% | -32723.0% | -8625.5% |
| — | — | +118.4% | +170.3% | +96.3% | +85.5% | +93.5% | +85.5% | +65.4% | +99.7% | +88.0% | +99.6% | — | — | +68.4% | -332.5% | — | — | -850.9% | -771.9% | -201.2% | |
| Net Margin | 6.9% | -49.6% | 13.2% | 52.8% | -11.2% | -37.7% | -74.7% | -78.9% | -285.4% | -257.2% | -1119.5% | -535.4% | -828.2% | -75166.7% | -9043.2% | -108718.2% | — | — | -29530.6% | -28059.5% | -8791.5% |
| — | -31.6% | +117.7% | +166.9% | +96.1% | +85.3% | +93.3% | +85.3% | +65.5% | +99.7% | +87.6% | +99.5% | — | — | +69.4% | -287.5% | — | — | -833.5% | -620.7% | -188.2% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 22.3% | -15.3% | 5.7% | 96.1% | -27.3% | -38.2% | -29.8% | -18.8% | -19.0% | -24.3% | -43.0% | -26.9% | -22.2% | -25.8% | -25.1% | -20.5% | -22.1% | -19.0% | -14.2% | -10.6% | -8.7% |
| — | +60.0% | +119.1% | +610.7% | -43.9% | -57.3% | +30.7% | +30.0% | +14.6% | +5.9% | -71.5% | -30.8% | -0.6% | -35.6% | -76.9% | -94.1% | -154.2% | -121.9% | -32.8% | +2.6% | +7.6% | |
| ROA | 9.3% | -7.8% | 2.8% | 27.9% | -4.4% | -9.3% | -9.6% | -7.2% | -10.0% | -16.3% | -27.1% | -17.6% | -15.2% | -17.9% | -17.7% | -14.5% | -16.4% | -15.4% | -11.9% | -9.0% | -7.5% |
| — | +15.8% | +129.5% | +487.2% | +56.5% | +42.9% | +64.5% | +59.1% | +34.1% | +8.9% | -52.7% | -21.1% | +7.2% | -15.9% | -48.8% | -61.8% | -119.6% | -107.9% | -33.3% | +0.4% | -1.3% | |
| ROIC | 27.1% | — | 8.2% | 121.7% | -21.6% | -35.0% | -24.7% | -13.6% | -16.8% | -21.7% | -35.3% | -22.2% | -21.0% | -27.5% | -24.5% | -23.3% | -24.2% | -30.5% | -27.3% | -27.1% | -21.3% |
| — | — | +133.3% | +993.1% | -28.8% | -61.4% | +30.1% | +38.6% | +19.9% | +21.3% | -44.4% | +5.0% | +13.4% | +9.6% | +10.5% | +13.9% | -13.4% | -23.9% | +30.4% | +53.5% | +47.6% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.10 | 0.09 | 0.08 | 0.10 | 0.58 | 0.49 | 0.37 | 0.40 | 0.34 | 0.29 | 0.43 | 0.46 | 0.37 | 0.25 | 0.24 | 0.25 | 0.28 | 0.17 | 0.15 | 0.13 | 0.14 |
| — | -80.7% | -77.0% | -74.1% | +71.2% | +69.5% | -13.4% | -13.9% | -8.8% | +17.1% | +77.6% | +85.0% | +30.9% | +42.9% | +61.4% | +89.5% | +107.4% | +63.7% | +20.6% | -27.1% | +2.8% | |
| Debt / EBITDA | 0.34 | — | 1.26 | 0.16 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 1.57 | 1.60 | 1.71 | 1.57 | 0.69 | 0.60 | 0.64 | 0.75 | 0.83 | 4.54 | 3.14 | 3.32 | 5.07 | 5.13 | 4.84 | 5.55 | 5.54 | 8.65 | 13.97 | 15.69 | 15.27 |
| — | +167.3% | +169.5% | +108.9% | -16.2% | -86.8% | -79.7% | -77.4% | -83.7% | -11.5% | -35.1% | -40.2% | -8.5% | -40.7% | -65.4% | -64.6% | -63.7% | -41.6% | -7.3% | +43.6% | +16.0% | |
| Quick Ratio | 1.57 | 1.60 | 1.71 | 1.57 | 0.69 | 0.60 | 0.64 | 0.75 | 0.83 | 4.54 | 3.14 | 3.32 | 5.07 | 5.13 | 4.84 | 5.55 | 5.54 | 8.65 | 13.97 | 15.69 | 15.27 |
| — | +167.3% | +169.5% | +108.9% | -16.2% | -86.8% | -79.7% | -77.4% | -83.7% | -11.5% | -35.1% | -40.2% | -8.5% | -40.7% | -65.4% | -64.6% | -63.7% | -41.6% | -7.3% | +43.6% | +16.0% | |
| Interest Coverage | 6.95 | — | 11.31 | 102.45 | -12.36 | -21.27 | -14.54 | -11.78 | -21.29 | -25.96 | -29.31 | -18.68 | -82.87 | -118.85 | -140.07 | -74.40 | -89.13 | -90.07 | -72.77 | -59.48 | -51.11 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying VXRT stock.
Vaxart, Inc.'s current P/E is 6.7x. The average P/E over the last 2 quarters is 4.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Vaxart, Inc.'s current operating margin is 7.6%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Vaxart, Inc.'s business trajectory between earnings reports.